The Cancer Letter

Inside information on cancer research and drug development

Funding Opportunities

DoD Melanoma Research Program anticipated funding opportunities for FY22

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The Melanoma Research Program anticipates several funding opportunities for FY22.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Roger Lo awarded $2M NIH grant to study melanoma treatment resistance

Roger Lo, professor of medicine, dermatology, and molecular and medical pharmacology and investigator at the UCLA Health Jonsson Comprehensive Cancer Center, was awarded a $2 million grant from NIH to investigate innovative strategies to prevent drug resistance in melanoma treatment and improve the effectiveness of MAPK inhibitors, a common treatment for patients with melanomas that carry the BRAFV600 mutation.
Clinical Roundup

Dysfunctional white blood cells linked to heightened melanoma risk

Mayo Clinic study has found that 8 million to 10 million Americans over age 40 have an overabundance of cloned white blood cells, or lymphocytes, that hamper their immune systems. Although many who have this condition—called monoclonal B-cell lymphocytosis—do not experience any symptoms, a recent study shows they may have an elevated risk for several health complications, including melanoma. 
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account